The era of chemotherapy, which started in the middle of the last century, has been ruled by the routine use of dose-intense protocols, based on the "maximum-tolerated dose" concept. By promoting a balance between patient's quality of life and the goal of rapidly killing as many tumour cells as possible, these protocols still play a prominent role in veterinary oncology.
| INTRODUCTION
Cancer challenges clinicians all over the world. In veterinary medicine, the incidence of age-related diseases, including cancer, has been increasing in recent years, mainly due to the improved general health of pets. [1] [2] [3] Chemotherapy stands out as the most effective systemic drug therapy in veterinary medical oncology. Since the 1970s, 4 cytotoxic drugs have been rationally used at high doses, following the "maximum-tolerated dose" concept, 5 what has allowed clinicians to minimize life-threatening side effects. 6 While the application of this classic form of chemotherapy has undoubtedly helped to treat cancer patients, permanent tumour control has been only occasionally achieved. 7 Alongside this, treated patients have suffered various grades of toxicity, which mainly result from the untargeted treatments affecting all rapidly dividing cells, 5 necessitating the existence of a break period between treatment sessions. 5, 8 Based on the belief that cancer chemotherapy shows antiangiogenic properties, 9 in 2000 some authors 8, 10, 11 started to treat tumours with small doses of chemotherapeutic agents for long periods of time, without any treatment interruptions. This high-dose to high-time transition of drug scheduling, resulted in a new chemotherapeutic modality that combats cancer in a completely different way.
This work will focus on the use of low-dose metronomic chemotherapy (MC) in canine species, a topic of intense research, since its first rational application at the year of 2000.
| DEFINITION
MC or low-dose MC, can be defined as the oral administration of chemotherapy at relatively low, minimally toxic doses, on a frequent or continuous schedule of treatment, with no extended drug-free breaks. 6, 8, 12 The concept is not entirely new, as physicians have been using longer-term maintenance chemotherapy to manage certain cancers in human oncology for decades. 5 However, the name was first suggested in 2000 by Hanahan et al, 8 and over the years, other terminologies have also been used, including continuous low dose 13 or continuous low-dose oral chemotherapy, 14 low-dose anti-angiogenic chemotherapy, 15 low-dose maintenance chemotherapy 16 and hightime chemotherapy. 17 
| MECHANISMS OF ACTION OF MC
Although initially considered to exert its effects exclusively through anti-angiogenic mechanisms, 8, 10, 11 over time MC has proven to be a multitarget therapy. 18 The most relevant mechanisms of action can be currently divided into 4 major groups: (1) the effect on neovascularization, (2) the effect on immune system, (3) the effect on cancer cells and cancer stem cells (CSCs) and (4) the induction of tumour dormancy.
| MC and neovascularization
Angiogenesis and vasculogenesis are essential for tumour growth. 19 Angiogenesis consists of the generation of new blood vessels from mature and rapidly dividing endothelial cells present in pre-existing capillaries. 9 Tumour angiogenesis is a highly complex process involving the participation of several players, including angiogenic molecules and cell types, such as endothelial cells, pericytes 20, 21 and bone marrow-derived precursor cells. 19 The capacity to activate angiogenesis, also called angiogenic switch, 7, 22 is an essential process for a tumour to move out from the quiescent state. 7 Angiogenesis takes place in microscopic pre-invasive lesions, and not only in the rapid growth phase of the tumour, as it originally was thought. 2, 19, 22 When exposed to MC, endothelial cells in the tumour vasculature are directly affected by the cytotoxic drugs 5, 23, 24 through a selective induction of apoptosis and selective inhibition of proliferation and migration. 18, 25, 26 These cells, are also indirectly In addition, metronomic schedules also interfere with vasculogenesis, which refers to, in contrast to angiogenesis, the formation of new blood vessels from bone marrow-derived circulating endothelial progenitor cells (CEPs), 19 the same cells responsible for the phenomenon of "tumour repopulation" or "rebound" 6 during the drug-free period between cycles of dose-intense chemotherapy. MC targets CEPs, 6, 27 blocks their mobilization and decreases their viability, 18, 23 and might even kill them. 24 Thus, by inhibiting angiogenesis and vasculogenesis, MC seems to have both a local and a systemic antineovasculogenic effect. 28 
| MC and the immune system
The immune system plays a key role in the development and control of cancer. 18 Immunosuppressive regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) are very important players limiting pathologic inflammation under both physiologic and cancerous conditions. 7 These cells efficiently suppress anticancer immune responses and are present at high levels in oncologic patients with active malignancies, 7 contributing to the establishment of neoplastic tolerance and malignity. [29] [30] [31] In the context of MC, Tregs are particularly remarkable. 18 By directly targeting these 3 compartments on multiple levels, which interact with one another, an additive or synergistic effect may be produced and MC can, in theory, induce a state of tumour dormancy, 16 leading to a long-term asymptomatic control of the disease. 18 Figure 1 illustrates the major events arising from metronomic treatment. Two different concepts have been used: "continuation maintenance," when one component of the initial therapy is continued after the induction phase, and "switch maintenance," in which a new agent is introduced. 46 More recently, a new treatment modality has been introduced-the chemo-switch regimen-referring to the use of low-dose MC after maximum-tolerated dose chemotherapy.
Chemo-switch as a maintenance approach may be of clinical benefit to patients with low tumour burden.
46,51
Kerbel and Kamen 6 were the first to suggest that combining both chemotherapeutic schedules might have a synergistic effect. One 
| Advantages of MC
In comparison with conventional schedules, low-dose MC has several advantages, making this new modality attractive for veterinary application. Overall, the main benefits of MC are: (1) better tolerability and reduced need for supportive medications, (2) generally low cost, (3) increased convenience to the pet-owners who treat their pets at home (also causing less stress to the animal), (4) lower probability of inducing acquired drug resistance and (5) possibility of combination with other regular and orally given targeted therapies.
5,28,36,54
| Cytotoxic agents used in metronomic regimen
Cyclophosphamide is by far the most widely studied drug. 45, 55 This drug is an alkylating agent which has been used successfully in the management of multiple malignancies, 55 with strong anti-angiogenic and immunomodulatory ability. 6, 55 When toxicity is encountered it is most commonly gastrointestinal. 56 Sterile haemorrhagic cystitis, a known complication of intravenous cyclophosphamide administration in dogs, may also be a problem in metronomic drug-scheduling; 14, 53, 57, 58 therefore it is important to administer the drug in the morning, to encourage water intake, to monitor urine production and, if necessary, to concurrently administer diuretics. 59, 60 Cyclophosphamide represents the basis of the majority of metronomic regimens, either alone or combined with other drugs. 55 However, its posology shows a great variability among metronomic 71 have also been used in canine patients with generally good tolerance.
| Other drugs used in combination with MC
MC is almost always applied to cancer patients in combination with other agents, 5 most commonly small molecules inhibitors (not discussed in this review) and other non-chemotherapeutic agents, such as the non-steroidal anti-inflammatory drugs (NSAIDs), metformin and thalidomide.
Inflammatory mediators are thought to play a critical role in the initiation and maintenance of cancer cell survival and growth. 84 Trial outcomes in dogs will be discussed below.
| CHALLENGES TO MC
Since its conception, MC has been facing considerable challenges.
The own definition of this modality, metronomic, is vague and lacks clear indications of the doses and posology, mismatching the Grade 1 GI toxicity (n = 4; 12.9%)
• Great clinical response, despite 94% of canine population under MC had undergone prior therapy that had become ineffective.
(Continued ) Carboplatin (300 mg/m 2 , IV, every 3 wk, for 4 cycles), after amputation (n = 45) (control group) Carboplatin (same dosage) with CYC (10 mg/m 2 , PO, EOD), after amputation (n = 35) (control group) Carboplatin (same dosage) with CYC (same dosage), after amputation (n = 81) (toceranib group) CYC (7 mg/ Low-grade toxicities, mainly GI and hematologic; SHC (n = 2 control; n = 5 toceranib-treated); temporary toceranib discontinuation due to AE (n = 10)
• No significant differences (on DFI, OST and 1-year survival 8 ) reported between the use and non-use of toceranib together with adjuvant chemotherapeutic protocol;
• More frequent treatmentrelated toxicities in toceranib group. None Not mentioned CYC-related toxicity (not specified) (n = 1) Transient GI and haematologic toxicoses (n = 3)
• Clinical stage was significantly determinant for the prognosis; • Adjuvant chemotherapy seemed to prolong ST of dogs post-splenectomy, but no significant difference was found (P = .40); • Longer OST in dogs treated with the combination DOX and CYC suggests a possible additive or synergetic effect between the 2 drugs, but no significant differences were reported among treatment groups. (Continued ) concept of precision medicine. 16 The lack of large randomized phase III trials in small animals that use MC and compare it with classic chemotherapy 16 is a major limitation, and the main reason for the metronomic skepticism-the lack of general acceptance of this modality. As a consequence, until enough evidence is put together, basic questions concerning efficacy, drug resistance, drug dosing, treatment duration and patient selection will remain incompletely answered.
Dose optimization, for instance, has been difficult to achieve because low-dose continuous protocols are not defined by doselimiting toxicities in the same manner as classic chemotherapy. 61 In addition, the response evaluation criteria in solid tumours (RECIST), The multiple drug resistance is an additional concern associated with the use of chemotherapy. Tumour resistance to cytotoxic drugs is a complex and probably multifactorial challenge, mediated by genetic and biochemical alterations that allow cancer population to survive during therapy. 86 Nevertheless, the understanding of the mechanisms involved in resistance to MC remains quite limited, 16, 87 with the majority of published studies focusing on acquired resistance to metronomic cyclophosphamide in human patients with prostate cancer, 88, 89 in whom the first molecular pathways were identified.
However, no clinical trials focusing on this issue have been published in veterinary medicine.
| CLINICAL STUDIES IN VETERINARY MEDICINE
Thanks to its characteristics, MC has gradually become a popular treatment option in companion animals. 7 Nonetheless, thus far, only 20 publications of clinical studies investigating metronomic drug 53 Adjuvant MTDC protocol (n = 12): DOX (30 mg/m 2 , IV, every 3 wk) alone for 4 to 5 cycles (n = 9), or in combination with dacarbazine (200 mg/m 2 /die, IV, for 5 consecutive days starting on the day of DOX, for 2 to 4 cycles) (n = 3) Adjuvant MTDC-MC protocol (n = 10): DOX (30 mg/m 2 , IV, every 3 wk) alone for 4 to 6 cycles (n = 8), or in combination with dacarbazine (200 mg/m 2 /die, IV, for 5 consecutive days starting on the day of DOX, for 4 cycles) (n = 2), followed by CYC ( 2 Only 52 dogs could be evaluated for toxicity.
3 Baseline plasma VEGF levels measured in 11 dogs.
4 Protocol applied to dogs.
5 Control group consisted of 10 dogs receiving MC alone, but the protocol was not specified. 6 Data available only for 30 dogs.
7 Data available only for 28 dogs.
8 Data from historical control groups used in calculations.
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